Adlyxin does not contain insulin. It is an injectable prescription drug that may improve blood sugar control in adults with type 2 diabetes when paired with diet and exercise.
Sanofi will offer Adlyxin as a single dose in a disposable pre-filled pen. Patients inject the drug once a day.
Adlyxin has already been approved in more than 60 countries around the world. The Paris-based drugmaker did not say when the treatment would hit the U.S. market.
More articles on the drug market:
FDA approves AbbVie’s drug to treat chronic hepatitis C
Sen. Bernie Sanders’ DNC speech tackles high prescription drug costs: 4 things to know
‘Pain refugees’ travel out of Montana for access to opioid prescriptions
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
